戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (right1)

通し番号をクリックするとPubMedの該当ページを表示します
1 eal-time response to food antigens in 22 of 36 patients; no responses were observed in 14 of 36 patients (CLE-) or any of
2  (>/=1 to </=2 log-reduction in 2 weeks; n = 2) virological responses were observed in 15 (83%) brincidofovir episodes co
3                                        Encouraging clinical responses were observed in 16 of 20 patients (80%) with advan
4                                                   Objective responses were observed in 17 (31.5%) of 54 patients randomly
5 irst 3 mo posttransplantation, CMV- and VZV-specific T cell responses were observed in 30.4% and 40.3% of study subjects
6                                                   Objective responses were observed in 4 out of 9 RT patients (44%) and i
7                                      Objective radiographic responses were observed in 53% of patients, and complete resp
8                                                    Cellular responses were observed in 57% of vaccine recipients tested a
9                                                       Tumor responses were observed in 9 patients with a median progressi
10                                           Rapid and durable responses were observed in a minority of patients.
11 o were treated at the highest dose level, objective partial responses were observed in a patient with esophageal cancer (
12                                         Strikingly, similar responses were observed in allergic patients and beekeepers a
13                        In contrast, asymmetrical phenotypic responses were observed in another parental pair, Cvi-0/Sha.
14                                                     Durable responses were observed in association with several histologi
15 n M. bovis-infected animals, PPDB specific IL-22 and IL-17A responses were observed in both CD4+ T cell and gammadelta T
16                                          Similar rod-driven responses were observed in both ventral and dorsal DACs.
17                                                          No responses were observed in controls.
18                                                  Spike-like responses were observed in each i-t response due to the compl
19 s (range, 58-75%) at well-tolerated doses, and two complete responses were observed in each treatment group.
20                                                   IFN-gamma responses were observed in ex vivo PBMC stimulated with E2 an
21 osed guinea pigs than in control animals; similar increased responses were observed in ex vivo vagus nerve and neuron cel
22                                               Deep, durable responses were observed in heavily treated patients.
23                    Interferon gamma-mediated, CD8(+) T-cell responses were observed in KPC and Kras(G12D/+);Pdx-1-Cre mic
24                 Remarkably, high-magnitude Env-specific IgA responses were observed in milk, surpassing those in plasma.
25                                                    Antibody responses were observed in most participants by day 14.
26 volved in key metabolic pathways of the cell, major genetic responses were observed in muscle.
27                        However, abnormal NK cell functional responses were observed in nearly one-third of patients (incl
28                                                     Partial responses were observed in one patient with uveal melanoma an
29                 In deaf cats, substantially reduced induced responses were observed in overall power as well as duration
30  amplified in patients with Lyme arthritis, and the highest responses were observed in patients with 1805GG in the antibi
31                                                No objective responses were observed in patients with CLL.
32                 Rapid and durable hematologic and molecular responses were observed in patients with essential thrombocyt
33                                                    Atypical responses were observed in patients with melanoma treated wit
34                                                             Responses were observed in patients with virus-positive tumor
35                                  Significant supra-additive responses were observed in right STS within the first 250 ms
36                                                         All responses were observed in RT patients who had progression af
37                                                     Partial responses were observed in seven of nine patients (78%), incl
38                        Furthermore, the strongest enhancing responses were observed in soils with high carbon-to-nitrogen
39                          High levels of M2e specific immune responses were observed in the 4M2e-tFliC MNP-boosted group a
40                                          Significant T-cell responses were observed in the absence of IFN-gamma-productio
41                            Nodulation factor-induced Ca(2+) responses were observed in the cbs1 mutant, indicating that M
42 gn was used with the study to be terminated if no confirmed responses were observed in the first 20 evaluable patients.
43                              Elevated IL-33 levels and ILC2 responses were observed in the lungs most likely due to oxida
44 nt positron emission tomography (PET) responses and 2 mixed responses were observed in these refractory tumors.
45 ould be evaluated, objective responses (complete or partial responses) were observed in those with non-small-cell lung ca
46                                      Transient haemodynamic responses were observed in time-locked association with 82 of
47 TCL subtypes, the overall response rate was 30%, whereas no responses were observed in tMF.
48 esponse was observed in a third ABC model, and intermediate responses were observed in two models of germinal center B-ce
49                                                   Strongest responses were observed in two models representing high-risk
50                                           Confirmed partial responses were observed in two patients carrying BRCA mutatio

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。